Andere talen Arcus Biosciences, Inc.

Aandelen

RCUS

US03969F1093

Biotechnologie & Medisch Onderzoek

Beurs gesloten - Nyse Andere beurzen 22:00:02 13-12-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
16,08 ^USD	-6,29%		-7,00%	-15,81%

06/11	Arcus Biosciences, Inc., Q3 2024 Earnings Call, Nov 06, 2024
06/11	Arcus Biosciences, Inc. Rapporteert de resultaten voor het derde kwartaal en de negen maanden eindigend op 30 september 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Arcus Biosciences Announces New Employment Inducement Grants	10/12
Arcus Biosciences Announces New Employment Inducement Grants	03/12
Arcus Biosciences to Participate in Two Upcoming Investor Conferences	19/11
Arcus Biosciences Announces New Employment Inducement Grants	12/11
Earnings Flash (RCUS) ARCUS BIOSCIENCES Reports Q3 Revenue $48M	06/11
Arcus Biosciences : Reports Third Quarter 2024 Financial Results and Provides a Pipeline Update Form 8 K	06/11
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update	06/11
Arcus Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	06/11
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer	05/11
Arcus Biosciences, Inc. Announces Domvanalimab Plus Zimberelimab Improved Overall Survival in Arc-10, A Randomized Study in Patients with Pd-L1-High Non-Small Cell Lung Cancer	05/11
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting	30/10
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting	30/10
First Clinical Data for Arcus Biosciences HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer	25/10
Arcus Biosciences Announces New Employment Inducement Grants	24/10
Health Care Down Amid Mixed Drug Developments -- Health Care Roundup	24/10
Arcus Biosciences Reports 'Encouraging' First Data for Casdatifan in Patients With Metastatic Kidney Cancer	24/10
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer	24/10
Arcus Biosciences, Inc. Announces Arcus Biosciences? HIF-2A Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer	24/10
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update	22/10
Arcus Biosciences Announces New Employment Inducement Grants	09/10
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium	09/10
Arcus Biosciences, Inc. to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium	09/10
Un retour au calme en trompe l'œil	03/10
En Direct des Marchés : TotalEnergies montre ses muscles, LVMH en F1, Casino maigrit	03/10
Borsa di Italia: Un ingannevole ritorno alla calma	03/10

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Arcus Biosciences, Inc.

Aandelen

RCUS

US03969F1093

Biotechnologie & Medisch Onderzoek

Andere talen

Filters